Researcher
Vigor Van Tendeloo
- Keywords:Medicine
- Disciplines:Innate immunity, Cancer therapy, Hematology, Vaccinology
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 31 Dec 2023 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2003 → 31 Dec 2018
Projects
1 - 10 of 31
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From1 Nov 2019 → 31 Oct 2020Funding: Nonprofit institution or equivalents
- Immune effector cell therapy for hematological malignancies with a focus on acute myeloid leukemia and multiple myeloma.From1 Oct 2019 → TodayFunding: FWO fundamental clinical research fellowship
- Vaccine & Infectious Diseases Excellence in Antwerp: Infectious disease prevention, control and management in a One Health policy context (VAX-IDEA).From3 Jul 2019 → 31 Dec 2023Funding: BOF - Methusalem, Fund Recuperation Fiscal Exemption
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From2 Jul 2019 → 1 Jul 2020Funding: Foundations, funds and other with scientific goal
- Unlocking the TCR repertoire for personalized cancer immunotherapies.From1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research Grant
- Improved RNA-based engineering of T lymphocytes with leukemia-specific T cell receptors to redirect their effector functions: towards a clinically safe platform to evaluate efficacy and potential off-target toxicity.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- An interdisciplinary study on the role of the HLA genes and T-cell diversity as risk factors for herpes zoster.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- Harnessing the expression of interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia: a functional and mechanistic characterizationFrom1 Oct 2017 → 12 May 2019Funding: FWO fellowships
- Wilms' tumor 1-specific T cell receptor (TCR) RNA-modified T cells for adoptive immunotherapy of cancer : moving towards clinical application.From1 Jan 2017 → 31 Dec 2018Funding: Foundations, funds and other with scientific goal
- Maximizing the anti-tumor potency of next-generation dendritic cell vaccines by combining interleukin-15 and in situ silencing of programmed-death ligands.From1 Jan 2017 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
Publications
41 - 50 of 125
- Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells(2017)
Authors: Heleen Van Acker, Ottavio Beretta, Sébastien Anguille, Lien De Caluwe, Angela Papagna, Johan Van den Bergh, Yannick Willemen, Herman Goossens, Zwi Berneman, Vigor Van Tendeloo, et al.
Pages: 13652 - 13665 - Characterization of interleukin-15-transpresenting dendritic cells for clinical use(2017)
Authors: Johan Van den Bergh, Evelien Smits, Maarten Versteven, Hans De Reu, Vigor Van Tendeloo, Eva Lion
- Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox(2017)
Authors: Benson Ogunjimi, Johan Van den Bergh, Pieter Meysman, Steven Heynderickx, K. Bergs, Elke Leuridan, Alex Vorsters, Herman Goossens, Kris Laukens, Nathalie Cools, et al.
Pages: 1 - 11 - Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia(2017)
Authors: Sébastien Anguille, Ann Van de Velde, Evelien Smits, Vigor Van Tendeloo, Gunnar Juliusson, Nathalie Cools, Barbara Stein, Eva Lion, Ann van Driessche, Irma Vandenbosch, et al.
Pages: 1713 - 1721 - Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells(2016)
Authors: Heleen Van Acker, Sébastien Anguille, Yannick Willemen, Johan Van den Bergh, Eva Lion, Evelien Smits, Vigor Van Tendeloo
- Immunological evasion of immediate-early varicella zoster virus proteins(2016)
Authors: Pieter Meysman, Dmitry Fedorov, Vigor Van Tendeloo, Benson Ogunjimi, Kris Laukens
Pages: 1 - 4 - The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells(2016)
Authors: Yannick Willemen, Johan Van den Bergh, Sarah M. Bonte, Sébastien Anguille, Carlo Heirman, Barbara Stein, Tessa Kerre, Kris Thielemans, Marc Peeters, Vigor Van Tendeloo, et al.
Pages: 73960 - 73970 - Generation and cryopreservation of clinical grade Wilms' tumor 1 mRNA-loaded dendritic cell vaccines for cancer immunotherapy(2016)
Authors: Evelien Smits, Barbara Stein, Eva Lion, Vigor Van Tendeloo, Yannick Willemen, Sébastien Anguille
Pages: 27 - 35 - Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium(2016)
Authors: Ann Van de Velde, Philippe Beutels, Evelien Smits, Vigor Van Tendeloo, Sébastien Anguille, A. Verlinden, Alain Gadisseur, Wilfried Schroyens, S. Dom, I. Cornille
Pages: 26 - 29 - Bisphosphonates for cancer treatment(2016)
Authors: Heleen Van Acker, Sébastien Anguille, Yannick Willemen, Evelien Smits, Vigor Van Tendeloo
Pages: 24 - 40
Patents
1 - 1 of 1
Linked dataset
1 - 1 of 1